Researchers at The University of Kansas Cancer Center have launched a clinical trial that eliminates radiation from the treatment protocol for an invasive type of breast cancer that accounts for one-fifth of all breast cancer patients.

In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to radionuclide therapy targeting prostate specific membrane antigen (PSMA) with the radionuclide lutetium-177 (177Lu). At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), researchers reported on a phase II prospective trial. Using gallium-68 positron emission tomography (PET) imaging, men who had exhausted conventional therapies were screened. Those with high PSMA-expression proceeded to 177Lu-PSMA617 (LuPSMA) therapy and experienced high response rates, which is clearly demonstrated in the PSMA PET imaging figure selected as the 2018 SNMMI Image of the Year.

A team of biologists has joined up with civil engineers to create what is believed to be the first 3-D computer model to show precisely how the tiny tubes that funnel milk through the breasts of mammals form. Understanding how such ducts form, the team says, may lend insight into how diseases such as metastatic breast cancers spread throughout the body. A report on the model was published April 9 in Developmental Cell.

Inadequate breast commission played a role in up to 38 percent of mammogram image quality deficiencies, according to a new article published by the U.S. Food and Drug Administration (FDA). The article is the second in a series examining the most common reasons for low-quality mammograms; the first article discussed the importance of patient positioning by the radiologic technologist.